KR20110128908A - 시르투인 조절제로서의 8-치환된 퀴놀린 및 관련 유사체 - Google Patents

시르투인 조절제로서의 8-치환된 퀴놀린 및 관련 유사체 Download PDF

Info

Publication number
KR20110128908A
KR20110128908A KR1020117023017A KR20117023017A KR20110128908A KR 20110128908 A KR20110128908 A KR 20110128908A KR 1020117023017 A KR1020117023017 A KR 1020117023017A KR 20117023017 A KR20117023017 A KR 20117023017A KR 20110128908 A KR20110128908 A KR 20110128908A
Authority
KR
South Korea
Prior art keywords
alkyl
substituted
fluoro
heterocycle
halo
Prior art date
Application number
KR1020117023017A
Other languages
English (en)
Korean (ko)
Inventor
치 비. 부
레베카 엘. 카사우본
Original Assignee
서트리스 파마슈티컬즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서트리스 파마슈티컬즈, 인코포레이티드 filed Critical 서트리스 파마슈티컬즈, 인코포레이티드
Publication of KR20110128908A publication Critical patent/KR20110128908A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020117023017A 2009-03-02 2010-03-02 시르투인 조절제로서의 8-치환된 퀴놀린 및 관련 유사체 KR20110128908A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15674909P 2009-03-02 2009-03-02
US61/156,749 2009-03-02

Publications (1)

Publication Number Publication Date
KR20110128908A true KR20110128908A (ko) 2011-11-30

Family

ID=42709991

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117023017A KR20110128908A (ko) 2009-03-02 2010-03-02 시르투인 조절제로서의 8-치환된 퀴놀린 및 관련 유사체

Country Status (11)

Country Link
EP (1) EP2403833A4 (pt)
JP (1) JP2012519211A (pt)
KR (1) KR20110128908A (pt)
CN (1) CN102414180A (pt)
AU (1) AU2010221417A1 (pt)
BR (1) BRPI1011477A2 (pt)
CA (1) CA2754058A1 (pt)
EA (1) EA201171098A1 (pt)
IL (1) IL214943A0 (pt)
MX (1) MX2011009213A (pt)
WO (1) WO2010101949A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009243006B2 (en) 2008-05-01 2013-03-21 Sirtris Pharmaceuticals, Inc. Quinolines and related analogs as sirtuin modulators
AU2009266889B2 (en) 2008-07-03 2013-05-02 Glaxosmithkline Llc Benzimidazoles and related analogs as sirtuin modulators
AU2009295946B2 (en) 2008-09-29 2013-03-21 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators
ES2574927T3 (es) 2009-10-29 2016-06-23 Glaxosmithkline Llc Piridinas bicíclicas y análogos como moduladores de sirtuina
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
US9126945B2 (en) 2011-03-18 2015-09-08 Bayer Intellectual Property Gmbh N-(3-carbamoylphenly)-1H-pyrazole-5-carboxamide derivatives and the use thereof for controlling animal pests
CN102250151B (zh) * 2011-05-17 2013-11-06 中国科学院化学研究所 2-芳亚胺-8-苯并咪唑喹啉过渡金属配合物及其制备方法与应用
RU2014111823A (ru) 2011-08-29 2015-10-10 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
JP6073343B2 (ja) 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
RU2014120168A (ru) * 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические азагетероциклы и аналоги в качестве модуляторов сиртуина
JP2015512891A (ja) 2012-03-13 2015-04-30 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 殺菌性ピリミジン化合物
EP2922540A1 (en) 2012-11-20 2015-09-30 F. Hoffmann-La Roche AG Substituted 1,6-naphthyridines
DK2970272T3 (en) 2013-03-14 2019-04-23 Merck Patent Gmbh glycosidase
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN105339368B (zh) 2013-06-04 2017-08-15 拜耳制药股份公司 3‑芳基‑取代的咪唑并[1,2‑a]吡啶及其用途
TWI529171B (zh) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 １，７－萘啶衍生物
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
US20160221964A1 (en) 2013-09-16 2016-08-04 Basf Se Fungicidal pyrimidine compounds
US10172915B2 (en) 2013-10-20 2019-01-08 Duke University Methods and compositions for activation of sirtuins with Annexin A1 peptides
JP6112724B2 (ja) * 2013-10-31 2017-04-12 日本化薬株式会社 １，５−ナフチリジン誘導体およびそれを有効成分として含んでなる殺虫剤
JP6229056B2 (ja) * 2013-11-12 2017-11-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 神経変性疾患の処置用の神経新生薬としてのピリド［４，３−ｂ］ピラジン−２−カルボキサミド
WO2015107133A1 (de) 2014-01-20 2015-07-23 Bayer Cropscience Ag Chinolinderivate als insektizide und akarizide
EP3107920B1 (de) 2014-02-19 2017-10-18 Bayer Pharma Aktiengesellschaft 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridine
US9771372B2 (en) 2014-05-23 2017-09-26 Active Biotech Ab Compounds useful as S100-inhibitors
US20160016951A1 (en) * 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors
MY187540A (en) 2014-08-01 2021-09-28 Nuevolution As Compounds active towards bromodomains
MA40532A (fr) 2014-08-28 2021-04-28 Asceneuron Sa Inhibiteurs de glycosidases
CN107001361A (zh) 2014-12-02 2017-08-01 拜耳医药股份有限公司 杂芳基取代的咪唑并[1，2‑a]吡啶及其用途
CN104592109A (zh) * 2015-01-19 2015-05-06 湖南华腾制药有限公司 一种8-溴喹啉衍生物的制备方法
WO2016128465A1 (en) * 2015-02-11 2016-08-18 Basilea Pharmaceutica Ag Substituted mono- and polyazanaphthalene derivatives and their use
JP2019506430A (ja) 2016-02-25 2019-03-07 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
EP3419971B1 (en) 2016-02-25 2022-04-20 Asceneuron SA Glycosidase inhibitors
MX2018010301A (es) 2016-02-25 2019-05-20 Asceneuron S A Sales de derivados de piperazina obtenidas por adicion de acidos.
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
WO2019037860A1 (en) 2017-08-24 2019-02-28 Asceneuron S.A. LINEAR INHIBITORS OF GLYCOSIDASE
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
JP2022522014A (ja) * 2019-02-28 2022-04-13 ケザール ライフ サイエンシズ タンパク質分泌阻害剤としてのチアゾール誘導体
CN110964011B (zh) * 2019-12-16 2022-06-21 诚达药业股份有限公司 一种8-氯-1,7-萘啶-3-甲醛的合成方法
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
AU2021300429A1 (en) 2020-07-02 2023-02-16 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
WO2024059212A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,6 western core compounds as mglu5 negative allosteric modulators and methods of making and using the same
WO2024059216A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,6 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same
CN117362286B (zh) * 2023-12-08 2024-03-12 清华大学 具有sirt6激动活性的化合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255318B1 (en) * 1997-12-11 2001-07-03 Biochem Pharma Inc. Antiviral compounds
FR2827599A1 (fr) * 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
SE0103649D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
WO2004080463A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
WO2006017672A2 (en) * 2004-08-03 2006-02-16 Serenex Inc. 2, 8-disubstituted naphthyridine derivatives
EP1856099A2 (en) * 2005-03-03 2007-11-21 Sirtris Pharmaceuticals, Inc. Acridine and quinoline derivatives as sirtuin modulators
CA2717011A1 (en) * 2008-02-28 2009-09-03 Novartis Ag Quinolines as inhibitors of farnesyl pyrophosphate synthase
AU2009243006B2 (en) * 2008-05-01 2013-03-21 Sirtris Pharmaceuticals, Inc. Quinolines and related analogs as sirtuin modulators
AU2009295946B2 (en) * 2008-09-29 2013-03-21 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators

Also Published As

Publication number Publication date
EP2403833A4 (en) 2012-08-29
AU2010221417A1 (en) 2011-09-22
EP2403833A1 (en) 2012-01-11
WO2010101949A1 (en) 2010-09-10
CA2754058A1 (en) 2010-09-10
JP2012519211A (ja) 2012-08-23
MX2011009213A (es) 2011-12-14
IL214943A0 (en) 2011-11-30
CN102414180A (zh) 2012-04-11
BRPI1011477A2 (pt) 2016-03-22
EA201171098A1 (ru) 2012-04-30

Similar Documents

Publication Publication Date Title
KR20110128908A (ko) 시르투인 조절제로서의 8-치환된 퀴놀린 및 관련 유사체
RU2519779C2 (ru) Хиназолинон, хинолон и родственные аналоги в качестве модуляторов сиртуина
JP5425891B2 (ja) サーチュイン調節薬としてのキノリンおよび関連する類似体
KR20110044291A (ko) 시르투인 조절제로서의 벤족사졸, 벤즈티아졸 및 관련 유사체
JP5758292B2 (ja) サーチュイン調節薬としてのベンズイミダゾールおよび関連する類似体
KR20110098789A (ko) 시르투인 조절제로서의 이소인돌리논 및 관련 유사체
KR20110102468A (ko) 시르투인 조절제로서의 프탈라지논 및 관련 유사체
KR20110079763A (ko) 시르투인 조절제로서의 피리딘, 비시클릭 피리딘 및 관련 유사체
KR20110110194A (ko) 티아졸로피리딘 시르투인 조절 화합물
KR20110019385A (ko) 시르투인 조절제로서의 이미다조피리딘 및 관련 유사체
JP6376707B2 (ja) サーチュイン調節剤としての置換架橋尿素類似体
KR20100038093A (ko) 시르투인 조절 이미다조티아졸 화합물
KR20120092141A (ko) 시르투인 조절제로서의 비시클릭 피리딘 및 유사체
JP2014530872A (ja) サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
KR20100051048A (ko) 시르투인 조절 티아졸로피리딘 화합물
KR20100086498A (ko) 가용화된 티아졸로피리딘
JP2014530870A (ja) サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid